No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US Stock MarketDetailed Quotes
HOWL Werewolf Therapeutics
- 1.590
- +0.020+1.27%
Close Dec 20 16:00 ET
- 1.590
- 0.000-0.01%
Post 20:01 ET
70.86MMarket Cap-1.05P/E (TTM)
1.630High1.490Low606.11KVolume1.550Open1.570Pre Close954.60KTurnover2.38%Turnover RatioLossP/E (Static)44.56MShares8.19452wk High0.79P/B40.48MFloat Cap1.38052wk Low--Dividend TTM25.46MShs Float23.990Historical High--Div YieldTTM8.92%Amplitude1.380Historical Low1.574Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference
Werewolf Therapeutics Analyst Ratings
Innovative Cytokine Immunotherapy: Werewolf Therapeutics' Pioneering Approach and Promising Pipeline
Werewolf Therapeutics Advances Innovative Cytokine Therapies
Leerink Partners Maintains Werewolf Therapeutics(HOWL.US) With Buy Rating, Maintains Target Price $13
Promising Potential of Werewolf Therapeutics' INDUKINE Platform Despite Challenges
Heat List
US
Overall
Symbol
Price
% Chg
No Data